Posted On: 10/05/2014 11:33:27 AM
Post# of 74553
$CELG Headlines
Be ready to play another market surge 12:25 p.m. Sept. 19, 2014 - The Trading Deck
14 stocks loved by top-performing fund managers 6:49 a.m. Sept. 18, 2014 - Philip van Doorn
Lululemon surges; RadioShack rebounds 3:24 p.m. Sept. 11, 2014 - Sue Chang
Major U.S. benchmarks rattle cage on first support 11:06 a.m. Sept. 10, 2014 - Michael Ashbaugh
Celgene shares up on news of positive late-stage drug trial 7:42 a.m. Sept. 4, 2014 - Ciara Linnane
How retail sector sets up stocks at the end of summer 3:32 p.m. Aug. 14, 2014 - The Trading Deck
S&P 500 retests the breakdown point 11:17 a.m. Aug. 14, 2014 - Michael Ashbaugh
S&P 500 ekes out another record close: stock market live blog recap 4:03 p.m. July 24, 2014 - blogs.marketwatch.com
Biotechs beat estimates, but the Street wants more 11:44 a.m. July 24, 2014 - Russ Britt
Biogen results crush consensus 4:55 p.m. July 23, 2014 - The Trading Deck
Nasdaq needs to turn up the volume 11:59 a.m. July 17, 2014 - The Trading Deck
Bull rolls on, but opportunities start to dwindle 1:52 p.m. July 10, 2014 - The Trading Deck
Reynolds rises on buyout report; Delta gains altitude 2:25 p.m. July 9, 2014 - Sue Chang
Celgene's arthritis drug fails a test, but company's stock rises anyway 1:23 p.m. July 9, 2014 - Russ Britt
Celgene shares slump as late-stage trial misses goal 7:27 a.m. July 9, 2014 - Ciara Linnane
S&P, Dow rattle cage on uncharted territory 11:20 a.m. July 1, 2014 - Michael Ashbaugh
S&P, Dow rattle cage on uncharted territory 10:54 a.m. July 1, 2014 - Michael Ashbaugh
Celgene's fourth stock split is a hit with investors as shares climb 1:02 p.m. June 19, 2014 - Russ Britt
Celgene shareholders approve 2-for-1 stock split 8:57 a.m. June 19, 2014 - Ciara Linnane
Celgene to increase buyback program to 1.15 bln shares from 575 mln 8:52 a.m. June 19, 2014 - Ciara Linnane
Individual Investor Portfolio: Major Sectors Are Beginning To Move In Opposing Directions 3:39 a.m. Oct. 4, 2014 - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan 8:09 p.m. Oct. 3, 2014 - TheStreet.com
Celgene (CELG) Highlighted As Momo Momentum Stock 10:14 a.m. Oct. 3, 2014 - TheStreet.com
Cramer's Lightning Round - Energy XXI Is The Worst Stock I've Ever Been Associated With (10/2/14) 6:18 a.m. Oct. 3, 2014 - Seeking Alpha
Cramer's Mad Money - Are U.S. Oil Producers In Trouble? (10/2/14) 6:02 a.m. Oct. 3, 2014 - Seeking Alpha
'Mad Money' Lightning Round: Buy, Buy, Buy Berkshire Hathaway 6:00 a.m. Oct. 3, 2014 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: Are You Ready to Profit From Friday's Panic? 8:02 p.m. Oct. 2, 2014 - TheStreet.com
Top Fund Buys: Chipotle, Allergan, Jazz, Gilead 5:25 p.m. Oct. 2, 2014 - Investors Business Daily
Second Oldest Stock Fund Is As Nimble As A Teenager 5:25 p.m. Oct. 2, 2014 - Investors Business Daily
Stock Market News for October 02, 2014 - Market News 10:10 a.m. Oct. 2, 2014 - Zacks.com
Makers of the 10 Top-Selling Cancer Drugs Catch the Eye of Analyst 8:02 a.m. Oct. 2, 2014 - 247WallSt.com
Celgene Is A Great Stock, But I Can't Manage To Hold Onto It 11:00 a.m. Oct. 1, 2014 - Seeking Alpha
Market Weakness Offers Traders a Second Shot at Celgene 8:14 p.m. Sept. 30, 2014 - InvestorPlace.com
Celgene Corporation Shares Could Head Higher 11:15 a.m. Sept. 30, 2014 - benzinga.com
Biotech Stocks Rebound On Strong Earnings, New Drugs 5:32 p.m. Sept. 29, 2014 - Investors Business Daily
Agios to Present Data on AG-120 in November, Shares Rises - Analyst Blog 5:30 p.m. Sept. 29, 2014 - Zacks.com
3 Stocks Reiterated As A Buy: PFE, CELG, BIIB 4:44 p.m. Sept. 29, 2014 - TheStreet.com
Celgene Has A Very Bright Future Ahead 4:26 p.m. Sept. 29, 2014 - Seeking Alpha
Bullish on Tech, Drug, Online Ed, and Solar 11:44 a.m. Sept. 29, 2014 - Barrons.com
3 Likely Biotech Buyout Candidates 7:48 a.m. Sept. 29, 2014 - 247WallSt.com
Regulatory Approvals, Lawsuits, Positive Study Results, Welfare Initiatives, and Technical Updates - Research Reports on Celgene, Actavis, Bristol-Myers Squibb, UnitedHealth and Vertex 9:20 a.m. Oct. 2, 2014 - PR Newswire - PRF
Celgene Corporation to Announce Third Quarter 2014 Results on October 23, 2014 8:30 a.m. Oct. 1, 2014 - BusinessWire - BZX
Oral OTEZLA® (apremilast) Approved by the U.S. Food and Drug Administration for the Treatment of Patients with Moderate to Severe Plaque Psoriasis 3:18 p.m. Sept. 23, 2014 - BusinessWire - BZX
Zeldes Haeggquist & Eck, LLP Announces Investigation of Celgene, Inc. 9:01 a.m. Sept. 22, 2014 - BusinessWire - BZX
Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 8:15 a.m. Sept. 19, 2014 - PR Newswire - PRF
Celgene Appoints Tuomo Pätsi as President of EMEAand Commits to Continue Delivering Innovative Solutionsto Meet Patient Needs Across the Region 8:02 a.m. Sept. 19, 2014 - BusinessWire - BZX
Study Data Release, Dividends and Shares Repurchases, Committee Recommendations, New Partners, and Upcoming Conferences - Research Reports on Celgene, Abbott, Actavis, UnitedHealth and Bristol-Myers 9:00 a.m. Sept. 16, 2014 - PR Newswire - PRF
Critical Alerts For CBS, Imperva Inc, Toyota Motor, Celgene and News Corp Released By InvestorsObserver 9:31 a.m. Sept. 11, 2014 - PR Newswire - PRF
New Center, Clinical Study Results, Collaborations, and Upcoming Event - Research Reports on Centene, Mallinckrodt, Infinity, Celgene and UnitedHealth 8:55 a.m. Sept. 8, 2014 - PR Newswire - PRF
Nuvilex Aims for Market Exclusivity with Orphan Drug Status While Eyeing Larger Cancer Market for Cell-in-a-Box Technology 9:06 a.m. Sept. 5, 2014 - ACCESSWIRE
Technical Data on Biotech Stocks - ARIAD Pharma, Tekmira Pharma, Arrowhead Research, Celgene, and Amgen 8:55 a.m. Sept. 4, 2014 - PR Newswire - PRF
Phase III FIRST™ (MM-020/IFM 07-01) Trial of REVLIMID® (lenalidomide) Plus Dexamethasone in Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for Stem Cell Transplant Published in New England Journal of Medicine 7:31 a.m. Sept. 4, 2014 - BusinessWire - BZX
VentiRx Pharmaceuticals Provides Corporate and Clinical Update 8:00 a.m. Sept. 2, 2014 - PR Newswire - PRF
Upcoming Conferences Schedule, Clinical Trial Data Release Schedule, Milestone Payment, and Expansion of Partnership - Research Reports on Celgene, Actavis, Regeneron, ISIS and UnitedHealth 9:10 a.m. Aug. 29, 2014 - PR Newswire - PRF
Acquisitions, Clinical Study Results, Dividends, and Technical Updates - Research Reports on Mallinckrodt, Celgene, Actavis, UnitedHealth and Bristol-Myers 8:50 a.m. Aug. 21, 2014 - PR Newswire - PRF
Celgene Corporation to Present at Investor Conferences in September 8:30 a.m. Aug. 21, 2014 - BusinessWire - BZX
Bristol-Myers Squibb and Celgene Enter Clinical Collaboration Agreement to Evaluate Immunotherapy and Chemotherapy Combination Regimen 8:00 a.m. Aug. 20, 2014 - BusinessWire - BZX
Clinical Study in the Journal of Clinical Oncology Reports Patients with Diffuse Large B-Cell Lymphoma Receiving Oral REVLIMID with Standard R-CHOP Achieved 98% Overall Response Rate and 80% Complete Response Rate 7:30 a.m. Aug. 19, 2014 - BusinessWire - BZX
Collaborations, Financial Results, and Technical Updates - Research Reports on Actavis, UnitedHealth, Bristol-Myers Squibb, Celgene and Aetna 8:40 a.m. Aug. 12, 2014 - PR Newswire - PRF
Critical Alerts For Advanced Micro Devices, Celgene, Weibo, SunPower, and Time Warner Released By InvestorsObserver 9:31 a.m. Aug. 5, 2014 - PR Newswire - PRF
Be ready to play another market surge 12:25 p.m. Sept. 19, 2014 - The Trading Deck
14 stocks loved by top-performing fund managers 6:49 a.m. Sept. 18, 2014 - Philip van Doorn
Lululemon surges; RadioShack rebounds 3:24 p.m. Sept. 11, 2014 - Sue Chang
Major U.S. benchmarks rattle cage on first support 11:06 a.m. Sept. 10, 2014 - Michael Ashbaugh
Celgene shares up on news of positive late-stage drug trial 7:42 a.m. Sept. 4, 2014 - Ciara Linnane
How retail sector sets up stocks at the end of summer 3:32 p.m. Aug. 14, 2014 - The Trading Deck
S&P 500 retests the breakdown point 11:17 a.m. Aug. 14, 2014 - Michael Ashbaugh
S&P 500 ekes out another record close: stock market live blog recap 4:03 p.m. July 24, 2014 - blogs.marketwatch.com
Biotechs beat estimates, but the Street wants more 11:44 a.m. July 24, 2014 - Russ Britt
Biogen results crush consensus 4:55 p.m. July 23, 2014 - The Trading Deck
Nasdaq needs to turn up the volume 11:59 a.m. July 17, 2014 - The Trading Deck
Bull rolls on, but opportunities start to dwindle 1:52 p.m. July 10, 2014 - The Trading Deck
Reynolds rises on buyout report; Delta gains altitude 2:25 p.m. July 9, 2014 - Sue Chang
Celgene's arthritis drug fails a test, but company's stock rises anyway 1:23 p.m. July 9, 2014 - Russ Britt
Celgene shares slump as late-stage trial misses goal 7:27 a.m. July 9, 2014 - Ciara Linnane
S&P, Dow rattle cage on uncharted territory 11:20 a.m. July 1, 2014 - Michael Ashbaugh
S&P, Dow rattle cage on uncharted territory 10:54 a.m. July 1, 2014 - Michael Ashbaugh
Celgene's fourth stock split is a hit with investors as shares climb 1:02 p.m. June 19, 2014 - Russ Britt
Celgene shareholders approve 2-for-1 stock split 8:57 a.m. June 19, 2014 - Ciara Linnane
Celgene to increase buyback program to 1.15 bln shares from 575 mln 8:52 a.m. June 19, 2014 - Ciara Linnane
Individual Investor Portfolio: Major Sectors Are Beginning To Move In Opposing Directions 3:39 a.m. Oct. 4, 2014 - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan 8:09 p.m. Oct. 3, 2014 - TheStreet.com
Celgene (CELG) Highlighted As Momo Momentum Stock 10:14 a.m. Oct. 3, 2014 - TheStreet.com
Cramer's Lightning Round - Energy XXI Is The Worst Stock I've Ever Been Associated With (10/2/14) 6:18 a.m. Oct. 3, 2014 - Seeking Alpha
Cramer's Mad Money - Are U.S. Oil Producers In Trouble? (10/2/14) 6:02 a.m. Oct. 3, 2014 - Seeking Alpha
'Mad Money' Lightning Round: Buy, Buy, Buy Berkshire Hathaway 6:00 a.m. Oct. 3, 2014 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: Are You Ready to Profit From Friday's Panic? 8:02 p.m. Oct. 2, 2014 - TheStreet.com
Top Fund Buys: Chipotle, Allergan, Jazz, Gilead 5:25 p.m. Oct. 2, 2014 - Investors Business Daily
Second Oldest Stock Fund Is As Nimble As A Teenager 5:25 p.m. Oct. 2, 2014 - Investors Business Daily
Stock Market News for October 02, 2014 - Market News 10:10 a.m. Oct. 2, 2014 - Zacks.com
Makers of the 10 Top-Selling Cancer Drugs Catch the Eye of Analyst 8:02 a.m. Oct. 2, 2014 - 247WallSt.com
Celgene Is A Great Stock, But I Can't Manage To Hold Onto It 11:00 a.m. Oct. 1, 2014 - Seeking Alpha
Market Weakness Offers Traders a Second Shot at Celgene 8:14 p.m. Sept. 30, 2014 - InvestorPlace.com
Celgene Corporation Shares Could Head Higher 11:15 a.m. Sept. 30, 2014 - benzinga.com
Biotech Stocks Rebound On Strong Earnings, New Drugs 5:32 p.m. Sept. 29, 2014 - Investors Business Daily
Agios to Present Data on AG-120 in November, Shares Rises - Analyst Blog 5:30 p.m. Sept. 29, 2014 - Zacks.com
3 Stocks Reiterated As A Buy: PFE, CELG, BIIB 4:44 p.m. Sept. 29, 2014 - TheStreet.com
Celgene Has A Very Bright Future Ahead 4:26 p.m. Sept. 29, 2014 - Seeking Alpha
Bullish on Tech, Drug, Online Ed, and Solar 11:44 a.m. Sept. 29, 2014 - Barrons.com
3 Likely Biotech Buyout Candidates 7:48 a.m. Sept. 29, 2014 - 247WallSt.com
Regulatory Approvals, Lawsuits, Positive Study Results, Welfare Initiatives, and Technical Updates - Research Reports on Celgene, Actavis, Bristol-Myers Squibb, UnitedHealth and Vertex 9:20 a.m. Oct. 2, 2014 - PR Newswire - PRF
Celgene Corporation to Announce Third Quarter 2014 Results on October 23, 2014 8:30 a.m. Oct. 1, 2014 - BusinessWire - BZX
Oral OTEZLA® (apremilast) Approved by the U.S. Food and Drug Administration for the Treatment of Patients with Moderate to Severe Plaque Psoriasis 3:18 p.m. Sept. 23, 2014 - BusinessWire - BZX
Zeldes Haeggquist & Eck, LLP Announces Investigation of Celgene, Inc. 9:01 a.m. Sept. 22, 2014 - BusinessWire - BZX
Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 8:15 a.m. Sept. 19, 2014 - PR Newswire - PRF
Celgene Appoints Tuomo Pätsi as President of EMEAand Commits to Continue Delivering Innovative Solutionsto Meet Patient Needs Across the Region 8:02 a.m. Sept. 19, 2014 - BusinessWire - BZX
Study Data Release, Dividends and Shares Repurchases, Committee Recommendations, New Partners, and Upcoming Conferences - Research Reports on Celgene, Abbott, Actavis, UnitedHealth and Bristol-Myers 9:00 a.m. Sept. 16, 2014 - PR Newswire - PRF
Critical Alerts For CBS, Imperva Inc, Toyota Motor, Celgene and News Corp Released By InvestorsObserver 9:31 a.m. Sept. 11, 2014 - PR Newswire - PRF
New Center, Clinical Study Results, Collaborations, and Upcoming Event - Research Reports on Centene, Mallinckrodt, Infinity, Celgene and UnitedHealth 8:55 a.m. Sept. 8, 2014 - PR Newswire - PRF
Nuvilex Aims for Market Exclusivity with Orphan Drug Status While Eyeing Larger Cancer Market for Cell-in-a-Box Technology 9:06 a.m. Sept. 5, 2014 - ACCESSWIRE
Technical Data on Biotech Stocks - ARIAD Pharma, Tekmira Pharma, Arrowhead Research, Celgene, and Amgen 8:55 a.m. Sept. 4, 2014 - PR Newswire - PRF
Phase III FIRST™ (MM-020/IFM 07-01) Trial of REVLIMID® (lenalidomide) Plus Dexamethasone in Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for Stem Cell Transplant Published in New England Journal of Medicine 7:31 a.m. Sept. 4, 2014 - BusinessWire - BZX
VentiRx Pharmaceuticals Provides Corporate and Clinical Update 8:00 a.m. Sept. 2, 2014 - PR Newswire - PRF
Upcoming Conferences Schedule, Clinical Trial Data Release Schedule, Milestone Payment, and Expansion of Partnership - Research Reports on Celgene, Actavis, Regeneron, ISIS and UnitedHealth 9:10 a.m. Aug. 29, 2014 - PR Newswire - PRF
Acquisitions, Clinical Study Results, Dividends, and Technical Updates - Research Reports on Mallinckrodt, Celgene, Actavis, UnitedHealth and Bristol-Myers 8:50 a.m. Aug. 21, 2014 - PR Newswire - PRF
Celgene Corporation to Present at Investor Conferences in September 8:30 a.m. Aug. 21, 2014 - BusinessWire - BZX
Bristol-Myers Squibb and Celgene Enter Clinical Collaboration Agreement to Evaluate Immunotherapy and Chemotherapy Combination Regimen 8:00 a.m. Aug. 20, 2014 - BusinessWire - BZX
Clinical Study in the Journal of Clinical Oncology Reports Patients with Diffuse Large B-Cell Lymphoma Receiving Oral REVLIMID with Standard R-CHOP Achieved 98% Overall Response Rate and 80% Complete Response Rate 7:30 a.m. Aug. 19, 2014 - BusinessWire - BZX
Collaborations, Financial Results, and Technical Updates - Research Reports on Actavis, UnitedHealth, Bristol-Myers Squibb, Celgene and Aetna 8:40 a.m. Aug. 12, 2014 - PR Newswire - PRF
Critical Alerts For Advanced Micro Devices, Celgene, Weibo, SunPower, and Time Warner Released By InvestorsObserver 9:31 a.m. Aug. 5, 2014 - PR Newswire - PRF
(0)
(0)
